Form DEFA14A Planet Labs PBC
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No. )
___________________________________
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
|
|
|
|
|
☐ |
Preliminary Proxy Statement |
||||
|
|
||||
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
||||
|
|
||||
☐ |
Definitive Proxy Statement |
||||
|
|
||||
☒ |
Definitive Additional Materials |
||||
|
|
||||
☐ |
Soliciting Material Pursuant to §240.14a-12 |
||||
PLANET LABS PBC
____________________________________________________________________________________
(Name of Registrant as Specified In Its Charter)
____________________________________________________________________________________
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
☒ |
|
No fee required. |
||||||||||||
☐ |
|
Fee paid previously with preliminary materials. |
||||||||||||
☐ |
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
||||||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Planet Labs (PL) call put ratio 3 calls to 1 put with a focus on July 35 calls as share price down 1.9%
- Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
- argenx to Host Autoimmune Myositis R&D Webinar
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
